Progressive Supranuclear Palsy
Conditions
Brief summary
This is a randomized, placebo-controlled trial of RT001 in patients with PSP.
Detailed description
This is a randomized, placebo-controlled trial of RT001 in patients with PSP to assess the efficacy, safety and tolerability of RT001. Subjects will be randomized to RT001 or placebo and will receive study drug for 48 weeks.
Interventions
DRUGRT001
RT001 8.64 g/d (3 capsules TID) for 1 month followed by 5.76 g/d (3 capsules BID) for an additional 11 months
DRUGPlacebo
Placebo Comparator: Placebo Inactive comparator capsule 960 mg/capsule: 3 capsules TID for 4 weeks, followed by 3 capsules BID for the remaining 44 weeks.
Sponsors
Biojiva LLC
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Sign the informed consent form prior to entry into the study 2. Male or female subject with age 40 years to 80 years at the time of signed consent 3. Meets the MDS-PSP study group criteria for possible or probable progressive supranuclear palsy with Richardson syndrome (postural instability and falls with vertical ocular motor dysfunction) 4. Presence of PSP symptoms for less than 4 years 5. Score of \<40 on the PSPRS-28 6. Ambulatory patients (with or without assistive device - no handheld help) and capable of performing study assessments/evaluations 7. Subject has an identified, reliable, study partner (e.g., caregiver, family member, social worker, or friend) who can assist in assuring that the subject is able to travel to the required visits. 8. Willing to provide the necessary blood samples
Exclusion criteria
1. Received treatment with other experimental therapies within the last 30 days prior to the first dose. The last dose of the prior experimental agent must have occurred more than 5 half-lives prior to enrollment in the current trial. 2. Previously received treatment with RT001 3. Refusal to discontinue fish oils or other oil-based supplements for the duration of the study (Screening/Baseline till last study procedure completed) 4. Mini mental state examination (MMSE) score less than 20 at screening 5. Subject resides at a skilled nursing or dementia care facility, or admission to such a facility is planned during the study period 6. Evidence of any clinically significant neurological disorder other than PSP in particular CBS 7. Evidence of a clear and robust benefit from levodopa at the time of screening. Participants are permitted to take levodopa and other Parkinson's medications if the dose had been stable for 60 days prior to screening 8. The subject has a history of or currently has schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-V or ICD-10 criteria 9. Subject has had a significant illness or infection requiring medical intervention in the past 30 days 10. Subject has evidence of any disease or condition (based on either history, physical or laboratory values) that might interfere with the conduct of the study 11. Is currently receiving active deep brain stimulation (DBS) that cannot be turned off 12. Any condition with a life expectancy of less than 2 years 13. Female who is breastfeeding or has a positive pregnancy test 14. Male participant or female participant of childbearing potential, who is sexually active and unwilling/unable to use a highly effective birth control method throughout the study 15. Unwilling or unable to comply with the requirements of this protocol, including the presence of any condition (physical, mental, or social) that is likely to affect the subject's ability to return for visits as scheduled 16. History, within the last 2 years, of alcohol abuse or physical opioid dependence
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in the PSPRS-28 at 48 weeks for the RT001 treated group vs placebo-treated group | 48 weeks | The PSPRS-28 is a clinician-rated instrument to assess disability and severity of PSP. The PSPRS-28 evaluates 28 items in six categories: daily activities (by history), behavior, bulbar, ocular motor, limb motor and gait/midline. |
Countries
Germany
Contacts
Primary ContactMark G. Midei, MD
Outcome results
None listed